NASDAQ:DBVT DBV Technologies Q4 2025 Earnings Results & Report $9.03 -0.52 (-5.45%) Closing price 10/13/2026 04:00 PM EasternExtended Trading$9.06 +0.04 (+0.39%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. DBV Technologies reported Q4 2025 earnings on February 14, 2026. The company reported EPS of -$1.15, while revenue was $0.65 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateFebruary 14, 2026TimeBefore Market Opens DBV Technologies EPS ResultsActual EPS-$1.15Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersDBV Technologies Revenue ResultsActual Revenue$0.65 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsDBV Technologies' Q3 2026 earnings is estimated for Wednesday, October 28, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesEarnings HistoryCompany Profile DBV Technologies Q4 2025 Earnings FAQ Did DBV Technologies beat earnings estimates for Q4 2025? DBV Technologies (NASDAQ:DBVT) reported earnings of -$1.15 per share for Q4 2025. The report was announced on Saturday, February 14, 2026. What was DBV Technologies' revenue for Q4 2025? DBV Technologies reported revenue of $0.65 million for Q4 2025. When is DBV Technologies' next earnings date? DBV Technologies' next earnings date is estimated for Wednesday, October 28, 2026. MarketBeat tracks confirmed and estimated earnings dates for DBV Technologies on the company's earnings history page. DBV Technologies Earnings HeadlinesDBV Technologies (NASDAQ:DBVT) Sets New 52-Week Low - Here's WhyOctober 8, 2026 | americanbankingnews.comDBV Technologies ADR (DBVT)September 30, 2026 | za.investing.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned. | Awesomely (Ad)DBV Seeks FDA Approval For VIASKIN Peanut Patch In Young ChildrenSeptember 30, 2026 | rttnews.comDBV Technologies Submits US FDA Application for Potential Pediatric Peanut Allergy PatchSeptember 30, 2026 | finance.yahoo.comDBV Submits BLA For VIASKIN Peanut Patch In Children With Peanut AllergySeptember 29, 2026 | rttnews.comSee More DBV Technologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like DBV Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DBV Technologies and other key companies, straight to your email. Email Address About DBV TechnologiesDBV Technologies (NASDAQ:DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s technology is designed to deliver therapeutic proteins through the skin without needles, with the goal of gradually modifying the immune system’s response to specific allergens. DBV Technologies’ principal product candidate is Viaskin Peanut, an investigational epicutaneous immunotherapy designed to expose patients to small amounts of peanut protein through a wearable patch. The company has evaluated the product primarily for peanut allergy, particularly in children, and has also explored its platform for other potential allergy indications, including milk allergy and related immune disorders. Founded in France, DBV Technologies has conducted research and clinical development activities in both Europe and the United States. The company’s programs have included late-stage clinical studies and regulatory interactions with U.S. and European authorities, although Viaskin Peanut remains an investigational product and is subject to regulatory review. DBV Technologies is headquartered in the Paris region of France and is listed on the Nasdaq under the symbol DBVT.View DBV Technologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
